RNA polymerase (pol) III synthesizes essential small RNAs, including tRNA and 5S rRNA. Wild-type p53 can repress pol III transcription both in vitro and in vivo. Many tumours carry substitutions in p53 which have selective eects on its functions. We identify tumourderived mutations that compromise the ability of p53 to regulate pol III transcription. Furthermore, substitution R175H, the most common mutation in cancers, converts p53 from a repressor to an activator of pol III. Oncoproteins neutralize p53 in some tumours; we show that human papillomavirus E6 and cellular hdm2 can both release pol III from repression by p53. These data suggest that the restraining in¯uence of p53 on pol III will be lost in many tumours. In addition to these features of sporadic cancers, some individuals inherit mutant forms of p53 and consequently suer from LiFraumeni syndrome, showing genetic predisposition to certain malignancies. We ®nd that pol III transcriptional activity is often highly elevated in primary ®broblasts from Li-Fraumeni patients, especially if the germline p53 mutation is followed by loss of the remaining allele. Our data suggest that p53 status can have a profound eect upon pol III transcription and hence on the biosynthetic capacity of cells.
Introduction
Inactivation of the tumour suppressor p53 is extremely common in cancers. About half of all sporadic human tumours carry mutations of one p53 allele coupled to deletion of the second allele (Hollstein et al., 1991 . In many of the remaining cases, wild-type p53 is neutralized by viral or cellular oncogene products (Momand et al., 1998; Vousden, 1995) . In all, it has been estimated that over 80% of human tumours contain mutations in p53 or the pathway that directly regulates it (Lozano and Elledge, 2000) . Mice that are homozygously null for the p53 gene are strongly predisposed to cancer, such that 74% develop tumours by the age of 6 months (Donehower et al., 1992) . Furthermore, inherited mutations in p53 can give rise to Li-Fraumeni syndrome (LFS), a familial cancer predisposition in humans (Varley et al., 1997a) . Approximately half the members of Li-Fraumeni families who inherit a mutated p53 allele develop cancer before they reach 30 years of age (Varley et al., 1997a) . Some mutant forms of p53 possess a dominant gain-of-function activity which can promote transformation and carcinogenesis even in the presence of a wild-type allele (Dittmer et al., 1993; Eliyahu et al., 1985; Finlay et al., 1989; Liu et al., 2000; Wolf et al., 1984) . Clearly, it is of great importance to understand fully how p53 operates.
A complex array of biochemical activities are displayed by p53, including the ability to regulate transcription (Cox and Lane, 1995; Haner and Oren, 1995; Ko and Prives, 1996; Levine, 1997; Sionov and Haupt, 1999; Vogelstein et al., 2000; Vousden, 2000) . It can bind to DNA in a sequence-speci®c fashion and stimulate expression of proximal genes (Bargonetti et al., 1991; Farmer et al., 1992; Kern et al., 1991; . As well as activating genes with p53-binding sites, p53 is also able to repress promoters that lack its response element (Cairns and White, 1998; Chesnokov et al., 1996; Crook et al., 1994; Farmer et al., 1996; Ginsberg et al., 1991; Horikoshi et al., 1995; Kley et al., 1992; Mack et al., 1993; Mercer et al., 1991; Ragimov et al., 1993; Santhanam et al., 1991; Seto et al., 1992; Subler et al., 1992; Sun et al., 2000; Venkatachalam et al., 1998; Werner et al., 1996; Yu et al., 1999; Zhao et al., 2000) . Although such repression occurs in the absence of a DNA site that is bound directly by p53, it is nevertheless highly speci®c; microarray analysis of *6000 genes showed that only 0.9% were inhibited by p53, whilst 1.8% were induced (Zhao et al., 2000) . Since some of the genes repressed by p53 encode promoters of cell cycle progression (Kley et al., 1992; Levy et al., 1993; Mercer et al., 1991; Venkatachalam et al., 1998; Yamamoto et al., 1994) , it has been suggested that the transcriptional repression function may contribute to the capacity of p53 to suppress proliferation and/or tumour formation (Cox and Lane, 1995; Ko and Prives, 1996; Neufeld and Edgar, 1998) . This possibility is supported by the fact that many tumour-derived p53 mutants have lost the capacity to inhibit transcription (Crook et al., 1994; Ginsberg et al., 1991; Mercer et al., 1991; Ragimov et al., 1993; Santhanam et al., 1991; Seto et al., 1992; Subler et al., 1992) . Furthermore, the Bcl-2 and adenoviral E1B 19kD oncoproteins can block speci®-cally the repression function of p53, without aecting its ability to activate expression (Shen and Shenk, 1994) .
Although most work has focused on pol II, p53 has also been shown to act as a general inhibitor of pol III transcription (Cairns and White, 1998; Chesnokov et al., 1996; Eichhorn and Jackson, 2001 ). Overexpression of p53, either in vitro or in transfected cells, can repress a range of pol III templates, including tRNA, 5S rRNA, VA and U6 snRNA genes (Cairns and White, 1998; Chesnokov et al., 1996; Eichhorn and Jackson, 2001) . Furthermore, the synthesis of tRNA and 5S rRNA is markedly elevated in ®broblasts from p53 7/7 knockout mice (Cairns and White, 1998) . p53 was shown to achieve these eects by binding and inhibiting the pol III-speci®c TBP-containing factor TFIIIB (Cairns and White, 1998; Chesnokov et al., 1996) . Thus, recombinant p53 interacts with TFIIIB in pull-down assays, whilst a subpopulation of endogenous p53 cofractionates and coimmunoprecipitates with endogenous TFIIIB (Cairns and White, 1998; Chesnokov et al., 1996) . TFIIIB activity is elevated speci®cally in p53 7/7 ®broblasts when compared with the corresponding wild-type cells (Cairns and White, 1998 ). An additional eect of p53 on the stability of TFIIIB has also been observed in a human ®broblast cell line (Eichhorn and Jackson, 2001) . TFIIIB is required for expression of all pol III templates, serving to recruit the polymerase to the promoter (Kassavetis et al., 1990; Paule and White, 2000) . The ability of p53 to regulate this factor therefore allows it to serve as a general repressor of pol III transcription (Cairns and White, 1998) . Since pol III is responsible for *10% of nuclear transcription, including the synthesis of tRNA and 5S rRNA, its control by p53 is likely to have a signi®cant eect on the biosynthetic capacity of cells.
The current study has examined how the ability of p53 to regulate pol III transcription is in¯uenced by various perturbations that occur in human tumours. The oncoproteins E6 and hdm2 are shown to release pol III from repression by p53 in vivo. Furthermore, several tumour-derived substitutions in the core domain of p53 are found to compromise its ability to regulate pol III. In addition, we have examined primary ®broblasts from LFS patients and found that in many cases pol III activity is abnormally elevated.
Results
Tumour-derived point mutations in p53 can disrupt its ability to repress pol III transcription p53 is mutated in about half of all human cancers . In 75% of these cases, the defect is a missense point substitution (Bullock et al., 2000) . Furthermore, 95% of the p53 mutations that arise in tumours occur within the central DNA-binding domain (Bullock et al., 2000) . Families with germline missense mutations in the central domain show a more highly penetrant cancer phenotype than families with truncating or other p53 inactivating mutations . We therefore tested whether the ability of p53 to repress pol III transcription is compromised by several substitution mutations in the central domain that were identi®ed originally in anogenital cancers (Crook and Vousden, 1992) . These mutants were transfected into the p53-negative osteosarcoma cell line SAOS2, as were the equivalent construct expressing wild-type p53 and the empty vector, as positive and negative controls, respectively. We cotransfected the adenovirus VA1 gene, as a reporter for pol III activity, and HSV-CAT, in which the chloramphenicol acetyltransferase gene is transcribed from the basal thymidine kinase promoter of herpes simplex virus, as an internal control for transfection eciency and RNA recovery. Expression of the VA1 and HSV-CAT reporters was then monitored by quantitative primer extension assays followed by phosphorimager analysis. Figure 1 presents the relative levels of pol III transcription, after normalizing the VA1 signal to the HSV-CAT internal control. It is clear that wild-type p53 represses the pol III-dependent expression of VA1, when compared with the empty vector. A 10-fold repression of VA1 transcription can be obtained with higher levels of transfected p53, but we chose to work with a constant input of just 2 mg of p53 expression vector so as not to reach saturation; this typically gives a threefold inhibition of VA1 expression, after normalization to the pol II control. In contrast, a p53 mutant in which arginine 175 is substituted to proline (R175P), originally described in a metastatic cervical carcinoma (Crook et al., 1994) , has substantially less capacity to repress pol III in SAOS2 cells. Nevertheless, the R175P mutant retains some weak ability to inhibit the level of VA1 expression. Similarly, R175P remains partially active in regulating pol II transcription (Crook et al., 1994) . It is signi®cant that R175P is severely compromised in pol III repression, because it retains near wild-type ability to suppress the proliferation of SAOS2 cells (Crook et al., 1994) ; this establishes that the cell cycle arrest function of p53 is insucient to account for the observed repression of pol III in vivo.
Another mutant that is able to transactivate various pol II reporters is R181L, which again lies within the core DNA-binding domain (Crook et al., 1994) . When tested against VA1, R181L is nearly as active as wildtype p53 in repressing pol III. In contrast, substitution R273C, within a highly conserved region of the DNAbinding domain, completely abolishes the ability of p53 to repress VA1 expression in SAOS2 cells. The R273C mutant is also completely inactive towards various pol II promoters (Crook et al., 1994) . Western blotting con®rmed that each of the mutants is expressed eciently in SAOS2 cells (Figure 1 , bottom panel), as previously reported (Crook et al., 1994) . These data reveal that pol III regulation by p53 can sometimes be compromised by substitutions that arise naturally in tumours.
The hot-spot mutation R175H converts p53 into an activator of pol III transcription in vivo
The most common substitution detected in cancer cells is mutation to histidine of p53 residue 175 within the DNA-binding domain (Ryan and Vousden, 1998) . We therefore tested the ability of mutant R175H to repress VA1 in vivo. SAOS2 cells were transfected with VA1, HSV-CAT and expression vectors encoding either wildtype p53 or the R175H p53 mutant. Western blotting showed that the two forms of p53 were expressed at comparable levels ( Figure 2 , third panel). As previously, wild-type p53 was found to inhibit VA1 expression speci®cally when compared to the activity seen in the presence of empty vector (Figure 2, graph and upper two panels). In contrast, no repression of VA1 was observed in response to R175H; instead, this mutant was found to stimulate the pol III reporter. Quantitation of several experiments revealed that 2 mg of R175H vector produces a *60% increase in VA1 expression after normalization against HSV-CAT to control for transfection eciency. These observations lead to the striking conclusion that the frequently occurring hotspot substitution R175H converts p53 from a repressor of pol III transcription into an activator.
Oncoproteins which neutralize p53 stimulate pol III transcription in vivo Apart from genetic mutation, p53 function can also be compromised in tumours through the action of various oncoproteins. For example, p53 is bound and inactivated by the E6 product of human papillomavirus (HPV) in many cervical carcinomas (Vousden, 1995 ; Figure 1 The ability of p53 to repress pol III transcription in vivo is sometimes compromised by point mutations that arose in tumours. SAOS2 cells were cotransfected with pVA1 (3 mg), HSV-CAT (3 mg) and 2 mg of empty vector (lane 1), or vector encoding wild-type p53 (lane 2) or p53R175P (lane 3), p53R181L (lane 4), or p53R273C (lane 5). RNA and protein were isolated 48 h after transfection. Primer extension analyses using primers speci®c for VA1 and CAT were carried out with the extracted RNA and then quantitated by PhosphorImager. Values shown are for VA1 expression after normalization to the levels of CAT RNA to correct for transfection eciency; they are given relative to the value obtained with empty vector (designated 100%) and represent the mean and standard deviation of three experiments. Underneath is shown a Western blot of extracted protein using anti-p53 antibody DO-1, to con®rm expression of transfected p53, and anti-actin antibody C-11, to con®rm equal loading of protein Figure 2 The R175H mutant form of p53 is unable to repress pol III transcription in vivo. SAOS2 cells were cotransfected with pVA1 (3 mg), HSV-CAT (3 mg) and 2 mg of empty vector (lane 1), 1 mg or 2 mg of vector encoding wild-type p53 (lanes 2 and 3, respectively), and 1 mg or 2 mg of vector encoding p53R175H (lanes 4 and 5, respectively). RNA and protein were isolated 48 h after transfection. The upper two panels show primer extension analyses of extracted RNA using primers speci®c for VA1 and CAT. The graph shows values determined by phosphorimager for VA1 expression after normalization to the levels of CAT RNA to correct for transfection eciency; they are given relative to the value obtained with empty vector (designated 100%) and represent the mean and standard deviation of three experiments. Underneath is shown a Western blot of extracted protein using anti-p53 antibody DO-1, to con®rm expression of transfected p53, and anti-actin antibody C-11, to con®rm equal loading of protein Werness et al., 1990) . We therefore tested whether E6 could block the ability of p53 to repress pol III transcription in vivo. SAOS2 cells were transfected with VA1, the HSV-CAT internal control and expression vectors encoding wild-type p53 and the E6 protein of HPV-16. Whereas p53 produced a speci®c repression of the pol III template, as previously, this eect was blocked by coexpression of E6 (Figure 3 , upper two panels). Western blotting con®rmed that E6 expression reduced the level of p53, without aecting the abundance of actin (Figure 3 , bottom two panels).
Mdm2 and its human counterpart hdm2 are cellular oncoproteins that can bind and inactivate p53 . Ampli®cation and overexpression of the gene encoding hdm2 is observed in many tumour types, especially osteosarcomas and soft tissue tumours (Momand et al., 1998) . As with E6, cotransfection of hdm2 was found to counteract the speci®c repression of pol III transcription by p53 ( Figure 4 , upper two panels). In contrast, an hdm2 mutant with a small deletion in its p53-binding domain (residues 59 ± 89) is unable to overcome repression of VA1. Western blotting con®rmed that the lack of eect of the mutant hdm2 is not due to inecient expression (Figure 4, middle panel) and that the level of p53 is speci®cally reduced with wild-type but not mutant hdm2 (Figure 4 , bottom two panels). We also observed a small but reproducible increase in expression by pol II of the HSV-CAT internal control in response to hdm2; this eect is p53-independent, since it also occurs with the D59 ± 89 mutant, and we have not investigated it further. We conclude that pol III activity in vivo can be in¯uenced by both E6 and hdm2, two oncoproteins that negate the function of p53 in human tumours.
Pol III transcriptional activity is often deregulated in primary fibroblasts from LFS patients Individuals who inherit mutant forms of p53 often suer from Li-Fraumeni syndrome, which involves a strong predisposition towards a range of tumour types (Varley et al., 1997a) . As with sporadic tumours, a wide variety of mutations can be associated with this inherited disease (Varley et al., 1997a) . We investigated whether the pol III machinery is deregulated in cells harbouring such mutations. Protein extracts were prepared from primary human ®broblasts derived from healthy volunteers or patients carrying inherited mutations in the p53 gene. Transcription assays were Figure 3 Repression of pol III transcription by p53 can be overcome by the E6 oncoprotein of HPV-16. SAOS2 cells were cotransfected with pVA1 (3 mg), HSV-CAT (3 mg) and 2 mg of empty vector (lanes 1 and 2) or vector encoding wild-type p53 (lanes 3 and 4) in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of 2 mg of pJ4O16.E6 encoding HPV-16 E6. RNA and protein were harvested 48 h after transfection. The upper two panels show primer extension analyses of extracted RNA using primers speci®c for VA1 (upper panel) and CAT (second panel). Underneath is shown a Western blot of extracted protein using anti-p53 antibody DO-1, to monitor expression of transfected p53, and anti-actin antibody C-11, to con®rm equal loading of protein Figure 4 Repression of pol III transcription by p53 can be overcome by the hdm2 oncoprotein. SAOS2 cells were cotransfected with pVA1 (3 mg), HSV-CAT (3 mg) and 2 mg of empty vector (lane 1) or vector encoding wild-type p53 (lanes 2 ± 4), along with vector (2 mg) encoding wild-type hdm2 (lane 3) or hdm2D59 ± 89 (lane 4). RNA and protein were harvested 48 h after transfection. The upper two panels show primer extension analyses of extracted RNA using primers speci®c for VA1 (upper panel) and CAT (second panel). Underneath is shown a Western blot of extracted protein using antibody Ab-1 against hdm2 (middle panel), antibody DO-1 against p53 (fourth panel) and anti-actin antibody C-11, to con®rm equal loading of protein (bottom panel) then carried out using the VA1 gene as template, to compare the activity of the pol III apparatus in normal and mutant cells. A representative example of such experiments is illustrated in Figure 5 . Lanes 1 ± 4 show the pol III activity in ®broblasts derived from volunteers who are presumed to carry only wild-type p53, whereas the remaining lanes show samples from 10 Li-Fraumeni patients who have inherited mutant forms of p53; each of these Li-Fraumeni patients carries a dierent mutation in p53, apart from 190MA and 19MA (lanes 13 and 14) who are unrelated but carry the same splicing mutation (Varley et al., 2001) . When compared to the normal samples, most of the Li-Fraumeni samples display elevated pol III activity. However, this is not invariably the case, since samples from patients 109MA and 163MA show only low levels of pol III transcription (lanes 7 and 8), despite carrying p53 substitutions (E180K and R248W, respectively). These eects are observed reproducibly in dierent batches of primary cells.
The level of wild-type p53 in healthy cells is controlled by a negative feedback loop involving mdm2; inactive p53 mutants are expressed at elevated levels due to their inability to induce mdm2 (Prives, 1998) . As expected, p53 is more abundant in the LiFraumeni samples than the normal controls, as revealed by Western blotting ( Figure 5 , middle panel). Blotting for actin con®rmed equal loading in each case ( Figure 5, lower panel) . Patient 109MA (lane 7) provides the sole exception to the overexpression of p53 mutants seen in the other Li-Fraumeni samples; this suggests that the E180K mutant may retain some capacity to regulate transcription, which is consistent with the fact that pol III activity remains repressed in this sample. Nevertheless, it is clear from the other samples that elevated pol III transcription can occur despite high levels of mutant p53, supporting the idea that naturally occurring mutations compromise the ability of p53 to repress pol III.
Although the adenovirus VA1 gene is a paradigm pol III template that is routinely employed as a reporter, we also tested in this assay a cellular class III gene encoding human tRNA Leu . This tRNA gene has a much weaker promoter than VA1 and gave little or no signal in the extracts from normal volunteers ( Figure 6, lanes 1 ± 4) . However, many of the LiFraumeni cell extracts transcribed the tRNA gene at signi®cantly higher rates (lanes 5 ± 15). The relative levels of tRNA Leu expression are similar to those of VA1, with the lowest activity again coming from 109MA and 163MA (lanes 7 and 8). An exception was provided by 168MA (lane 10), carrying an R273H substitution, which gave ecient transcription with VA1, but not with tRNA Leu . The activation seen with 196MA (lane 9), carrying a T265K mutation, is also less dramatic for tRNA Leu when compared to VA1. The reason for these dierences is unclear, as tRNA and VA genes are believed to utilize the same set of transcription factors (Paule and ; however, it may re¯ect subtle dierences between the two promoters. These data suggest that the pol III machinery is deregulated in a substantial proportion of LFS cases. Since each of the patients has a dierent genetic background, one cannot conclude that the elevated transcriptional activity results solely from changes in p53. Nevertheless, the results are striking and are consistent with the data from the transient transfections, which demonstrate more directly that naturally occurring mutations in p53 can compromise its ability to restrain pol III activity. Furthermore, these Li-Fraumeni data have the advantage over transfections that p53 is being expressed at physiolo- gical levels in a more natural cellular context than the SAOS2 line.
Patients with LFS who inherit a mutation in p53 nevertheless retain one wild-type copy of the gene. However, the ®broblasts from patient 161MA-F were found to have deleted their wild-type p53 gene. This may be explained by the fact that these cells were obtained during surgery to remove a tumour (Varley et al., 1996) . Nevertheless, they were isolated from precancerous tissue and are untransformed and slow growing, like all the Li-Fraumeni ®broblasts examined in this study. In comparison with normal or heterozygous ®broblasts, the cells from 161MA-F display exceptionally high pol III transcriptional activity ( Figure 6, lane 15) . Multiple batches of the 161MA-F ®broblasts, which carry only mutant p53, displayed substantially higher pol III activity than any of the other samples tested, with VA1, tRNA and U6 gene templates. These observations raise the possibility that deletion of the wild-type p53 gene from heterozygotes may result in further deregulation of the pol III machinery. To test this, we took heterozygous cells from patient 19MA, carrying a mutation in the splice donor site of exon 3; these were cultured through an additional nine passages, which proved sucient to induce the spontaneous loss of the wild-type allele.
When the resultant cells were tested for pol III activity, it was found to have become dramatically elevated ( Figure 7 , lanes 5 and 6). The same result was obtained when heterozygous 163MA cells (with the R248W substitution) were passaged until they had lost the wild-type p53 gene (Figure 7, lanes 3 and 4) . Thus, a complete loss of wild-type p53 in these human cells correlates with substantial activation of pol III transcription. This is consistent with the previous observation that tRNA and 5S rRNA synthesis is strongly elevated in ®broblasts derived from p53-knockout mice (Cairns and White, 1998) . Western blotting con®rmed that mutant p53 continues to be expressed in the late passage samples displaying high VA1 transcription. The data suggest that pol III activity in vivo is held in check by wild-type p53, whereas some naturally-occurring mutant forms are unable to exert this restraining in¯uence.
Discussion
Experiments with cells from knockout mice have shown previously that endogenous p53 contributes signi®cantly towards the control of pol III transcription in vivo (Cairns and White, 1998 ). In the current study, we have investigated how this regulation may be aected by perturbations to p53 that occur commonly in human tumours and also in untransformed cells from patients with LFS, an inherited condition which predisposes the aicted to certain types of cancer. We have shown that the oncoproteins E6 and hdm2 can release pol III from repression by p53. Furthermore, the ability of p53 to repress pol III transcription can also be compromised by various tumour-derived mutations.
Since E6 and hdm2 promote the degradation of p53 through ubiquitin-mediated proteolysis (Haupt et al., 1997; Kubbutat et al., 1997; Schener et al., 1993) , it is not surprising that these oncoproteins deregulate pol III transcription; in eect they are able to ablate p53 and produce a similar eect to a p53 knockout. Nevertheless, it was important to con®rm that E6 and hdm2 do indeed stimulate pol III transcription, as both are important aetiological agents in the development of speci®c types of human cancer. It was far less predictable how the pol III system would respond to the more subtle perturbations that are generally associated with mutation of the p53 gene. Most of these cases involve missense substitutions, and 95% of them are located within the central sequence-speci®c DNA-binding domain (Bullock et al., 2000) . p53 appears to repress pol III templates such as VA1 through protein ± protein interactions with TFIIIB, rather than direct binding to a DNA site at class III genes (Cairns and White, 1998; Chesnokov et al., 1996) ; it was therefore unclear whether the sequencespeci®c DNA-binding domain would be important for this function. Nevertheless, our data clearly establish that regulation of pol III transcription can be in¯uenced dramatically by substitutions within the central domain. This might be explained by conformational changes in the p53 molecule or the possibility that this domain is involved directly in protein ± protein interactions with TFIIIB.
The R175H substitution accounts for *6% of the missense mutations identi®ed in human cancers . When compared with other p53 mutants, it is found to be the most tumorigenic in a variety of assays (Dittmer et al., 1993; Finlay et al., Figure 7 Deletion of wild-type p53 correlates with increased pol III transcriptional activity in extracts of primary ®broblasts from LFS patients. (Upper panel). pVA1 (250 ng) was transcribed using whole cell extract (15 mg) of primary ®broblasts from two healthy volunteers (lanes 1 and 2) or from LFS patients 163MA (lanes 3 and 4) and 19MA (lanes 5 and 6). Whereas the cells used in lanes 3 and 5 have retained one wild-type copy of the p53 gene, the cells in lanes 4 and 6 were harvested at later passages and have deleted the wild-type p53 allele. The same extracts (20 mg) were analysed by Western blotting for levels of p53 (middle panel) and actin (lower panel) 1989). It displays a high metastatic potential in transgenic mice (Liu et al., 2000) and is associated with an extremely poor prognosis in human cancer victims (Goh et al., 1995) . It may therefore be signi®cant that this mutant has not only lost its ability to repress pol III transcription, but actually displays a capacity to stimulate expression of a pol III template when transfected into SAOS2 cells. At present it is unclear how this stimulatory activity might occur mechanistically, but there are precedents for such behaviour. For example, the promoter of the gene encoding the insulin-like growth factor I receptor is repressed by wild-type p53 but stimulated by certain tumour-derived p53 mutants (Werner et al., 1996) . Similar observations have been reported for the gene encoding matrix metalloproteinase-13 (Sun et al., 2000) .
In contrast to R175H, the less common R175P mutant from an anogenital tumour has retained some capacity to repress VA1 transcription, although it is clearly less potent than wild-type p53. This mutant was also reported to be partially compromised in its ability to transactivate the mdm-2 promoter and repress the cfos and SV40 early promoters (Crook et al., 1994) . However, its capacity to repress the cytomegalovirus immediate-early promoter is almost completely abolished (Crook et al., 1994 ). An even more drastic eect upon repression of pol II transcription results from the R181L substitution, which severely compromises the ability of p53 to repress a variety of targets, including the SV40 early promoter (Crook et al., 1994) . In contrast, R181L transactivates pol II transcription as eciently as wild-type p53 (Crook et al., 1994) and has retained most of its capacity to inhibit VA1 expression. These observations suggest that dierent structural and/or functional parameters are required for p53 to repress pol II and pol III promoters, since the two systems respond very dierently to the R181L substitution.
Pol III transcriptional activity was found to be signi®cantly elevated in primary ®broblasts of many patients from Li-Fraumeni kindreds that inherit mutant forms of p53. Like the use of knockout mice, this system can provide insight into the function of endogenous p53 present at physiological concentrations, in contrast to overexpression resulting from transient transfection. In several cases, such as 196MA who carries a T256A substitution, pol III transcription is activated very dramatically despite the presence of a wild-type p53 allele. The level of this activation, which can be 20-fold or more, is much greater than might be expected from a simple halving of dosage. However, previous studies have revealed that dramatic eects can result in vivo from the loss of a single p53 allele. For example, heterozygous p53 +/7 mice develop tumours at a substantially elevated rate; thus, 495% of heterozygotes have died or developed cancers by 2 years of age, against 20% of their wild-type littermates (Venkatachalam et al., 1998) . This is not simply due to loss of the remaining allele, since many of the tumours were found to express functional wild-type p53 (Venkatachalam et al., 1998) . Furthermore, whereas p53 7/7 mice usually develop lymphomas, the heterozygotes display a range of cancers, including carcinomas and sarcomas (Donehower, 1996) . Indeed, the tumour spectrum of the p53 +/7 mice resembles that of Li-Fraumeni families and these heterozygous mice may make a useful animal model for LFS (Donehower, 1996) . Clearly inactivation of a single allele can have dramatic eects, as appears to be the case for pol III transcription in some Li-Fraumeni ®broblasts. However, loss of the remaining allele may result in further deregulation, as is suggested by the data in Figure 7 .
It is important to remember that the dramatic eects we see in LFS ®broblasts are only correlative; there is no formal proof that the mutations in p53 are directly responsible for the changes we observe in pol III activity. Indeed, comparison of the wild-type ®bro-blasts from unaected volunteers shows some variation in transcriptional activity, which probably re¯ects the dierent genetic backgrounds. On the other hand, it is reassuring that 190MA and 19MA give similar levels of pol III transcription ( Figure 5 , lanes 13 and 14), since both carry mutations in the splice donor site of exon 3 (Varley et al., 2001) . Certainly, the frequent and dramatic deregulation of pol III that we see in LiFraumeni cells is very striking and clearly suggests that endogenous p53 can have a strong in¯uence on pol III activity in primary human ®broblasts. It also implies that naturally-occurring mutations in p53 will often compromise its ability to repress pol III, a contention that is supported by our transient transfection assays.
Abnormally high levels of pol III products are found in a wide range of transformed and tumour cell lines . This is also true of naturally occurring tumours, as shown by in situ hybridization, RT ± PCR and Northern analyses (Chen et al., 1997a,b; Winter et al., 2000) . A variety of mechanisms may contribute to this deregulation. For example, activation of Ras can stimulate pol III transcription in vivo . Clinically important tumour viruses can also increase pol III activity, such as hepatitis B virus and human T-cell leukaemia virus type 1 (Au®ero and Schneider, 1990; Gottesfeld et al., 1996; Wang et al., 1995 Wang et al., , 1997 . The pol III-speci®c transcription factor TFIIIC2 is frequently overexpressed in ovarian carcinomas . However, loss of repression by tumour suppressors may be the most frequent cause of deregulated pol III activity in transformed cells. The retinoblastoma protein RB has been shown to bind TFIIIB and block its interactions with TFIIIC2 and pol III, thereby potently inhibiting transcription (Chu et al., 1997 , Larminie et al., 1997 Sutclie et al., 2000; White et al., 1996) . This function is compromised by a number of mutations which arose naturally in human carcinomas Sutclie et al., 2000; White et al., 1996) . Pol III transcription is released from repression by E7, E1A and SV40 large T antigen, three viral oncoproteins which bind to RB (Larminie et al., 1999; Sutclie et al., 1999; White et al., 1996) . In a high proportion of cancers, the function of RB is compromised due to its hyperphosphorylation; this can be caused by overexpression of cyclin D or loss of p16, a speci®c inhibitor of cyclin D-dependent kinases (Bates and Peters, 1995; Hunter and Pines, 1994) . We have shown recently that hyperphosphorylation of RB prevents its binding to TFIIIB and that pol III transcription increases in vivo if cyclin D1 is overexpressed or p16 is depleted (Scott et al., 2001) . Thus, loss of RB function through a variety of mechanisms is likely to contribute substantially to the deregulation of pol III in a wide range of transformed cell types . The data in this manuscript suggest that changes to p53 are also likely to deregulate pol III transcription in many types of tumour. The E6 product of human papillomavirus is expressed in the majority of cervical carcinomas (Vousden, 1995; Werness et al., 1990) and we have shown that this oncoprotein can release the pol III system from repression by p53. Indeed, we have found recently that the production of tRNA is abnormally elevated in tumour tissue from patients with HPV-positive cervical cancer (D Arvanitis, D Spandidos and R White, in preparation). Similarly, Figure 4 shows that pol III transcription can also be derepressed by hdm2, which is overexpressed in many cancers, especially osteosarcomas and soft tissue tumours (Momand et al., 1998) . In addition, we have shown that the ability of p53 to restrain pol III activity is sometimes compromised by mutations in its central core domain that arise frequently in cancers . Most notably, the R175H substitution appears to convert p53 into an inducer of pol III transcription. This mutation is the most common substitution detected in tumours (Ryan and Vousden, 1998) and is associated with an extremely poor prognosis in patients (Goh et al., 1995) . Overall, it is estimated that over 80% of human tumours carry mutations in p53 or the pathways that regulate it (Lozano and Elledge, 2000) . It therefore seems probable that TFIIIB will be released from the restraining in¯uence of p53 in many malignancies. This is likely to contribute signi®cantly to the abnormal elevation of pol III activity that is so frequently observed in human cancers and may rank alongside the inactivation of RB as one of the most important mechanisms driving deregulation of pol III transcription.
Materials and methods

Plasmids
The pVA1 and pLeu plasmids contain the adenovirus VA1 gene and a human tRNA Leu gene, respectively (White et al., 1989 (White et al., , 1995 . HSV-CAT contains the CAT gene driven by the thymidine kinase promoter of Herpes Simplex Virus. The p53 expression constructs have been described previously (Baker et al., 1990; Crook et al., 1994) , as have the pJ4O16.E6 (Storey et al., 1988) and hdm2 constructs (Loughran and La Thangue, 2000) .
Transfection assays
The human osteosarcoma cell line SAOS2 was cultured in Dulbecco's modi®ed Eagle's medium (DMEM) with 10% fetal calf serum. Cells were transiently transfected using the calcium-phosphate precipitation method. DNA precipitates were left on the plates overnight and then the cells were washed with PBS and cultured for 48 h before harvesting. Total RNA was extracted using TRI reagent (Sigma), according to the manufacturer's instructions. It was then analysed by primer extension using both VA1-speci®c (5'-CACGCGGGCGGTAACCGCATG-3') and CAT-speci®c (5'-CGATGCCATTGGGATATATCA-3') labelled primers. Primer extension reactions were conducted as previously described (White et al., 1996) .
Li-Fraumeni cells
Mutations in the p53 genes of Li-Fraumeni families were identi®ed by direct genomic sequencing of all 11 exons plus the promoter region and all splice junctions (Varley et al., 1997a,b) . The cases examined in this study carried the following mutations in p53: 194MA, P152L; 138MA, R175H; 109MA, E180K; 163MA, R248W; 196MA, T256A; 168MA, R273H; 193MA, a stop codon at R209; 191MA, a mutation in the splice acceptor of intron 3; 190MA and 19MA both carry mutations in the splice donor site of exon 3; 161MA-F, L344P combined with loss of the wild-type allele.
Primary ®broblasts were cultured from skin biopsies obtained with informed consent from LFS patients and normal control individuals, as previously described (Boyle et al., 1998) .
Preparation of extracts and transcription assays
Whole cell extracts were prepared in high salt from small quantities of primary human ®broblasts using a freeze-thaw procedure, as previously described (White et al., 1995) . Transcription reactions were carried out as previously (White et al., 1989) , except that pBR322 was not included and the incubations were for 60 min at 308C.
Antibodies and Western blotting
Western immunoblot analysis was performed as previously described (White et al., 1995) using anti-p53 antibody DO-1 (Santa Cruz), antibody Ab-1 against hdm2 (Calbiochem) and antibody C-11 against actin (Santa Cruz).
